James Harrison, blood donor whose rare plasma saved millions of babies, dead at 88
James Harrison, a prolific Australian blood donor famed for having saved the lives of more than two million babies, has died at age 88.
Harrison, whose plasma contained a 'rare and precious antibody' known as Anti-D, donated blood more than 1,100 times, according to Australian Red Cross Lifeblood, which confirmed his death in a statement published Saturday.
Harrison, who was known as the 'Man with the Golden Arm,' died in his sleep at a nursing home north of Sydney on February 17, according to the statement.
Harrison's altruistic mission was driven by having received multiple blood transfusions following lung surgery at the age of 14.
He started donating plasma at 18 and did so every two weeks until he was 81, the upper age limit for blood donation in Australia.
Lifeblood Chief Executive Officer Stephen Cornelissen hailed Harrison's dedication.
'James was a remarkable, stoically kind, and generous person who was committed to a lifetime of giving and he captured the hearts of many people around the world,' Cornelissen said in the statement.
'James extended his arm to help others and babies he would never know a remarkable 1173 times and expected nothing in return.'
Harrison's daughter, Tracey Mellowship, said her father 'was a humanitarian at heart.'
'As an Anti-D recipient myself, he has left behind a family that may not have existed without his precious donations,' she said in the statement.
'He was also very proud to have saved so many lives, without any cost or pain. It made him happy to hear about the many families like ours, who existed because of his kindness.'
Anti-D is used to make a medication administered to pregnant mothers whose blood would attack their unborn babies' blood cells, known as rhesus disease.
The condition develops when a pregnant woman has rhesus-negative blood (RhD negative) and the baby in her womb has rhesus-positive blood (RhD positive), inherited from its father.
If the mother has been sensitized to rhesus-positive blood, usually during a previous pregnancy with an rhesus-positive baby, she may produce antibodies that destroy the baby's 'foreign' blood cells.
In the worst cases, babies can be brain damaged or die.
Anti-D, produced with Harrison's antibodies, prevents women with rhesus-negative blood from developing RhD antibodies during pregnancy.
The discovery of Harrison's antibodies was an absolute game-changer, Australian officials said.
'In Australia, up until about 1967, there were literally thousands of babies dying each year, doctors didn't know why, and it was awful. Women were having numerous miscarriages and babies were being born with brain damage,' Jemma Falkenmire, of the Australian Red Cross Blood Service, told CNN in 2015.
'Australia was one of the first countries to discover a blood donor with this antibody, so it was quite revolutionary at the time.'
Considered a national hero, Harrison won numerous awards for his generosity, including the Medal of the Order of Australia, one of the country's highest honors.
CNN's Doug Criss contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
3 hours ago
- Yahoo
A second Australian IVF mix-up shakes clinic and industry
By Byron Kaye and Kumar Tanishk (Reuters) -One of Australia's top IVF providers mistakenly implanted a patient with her own embryo instead of her partner's in a second fertility clinic mix-up, heightening concerns about an industry that did not have much active government oversight until recently. Monash IVF said the error took place on June 5 at a clinic in Melbourne but did not provide further details such as how it learned of the bungle or what the couple planned to do next. The company said it was supporting the couple, who it did not identify. It said the patient's embryo was mistakenly implanted under a treatment plan which called for an embryo from the patient's partner to be transferred. The incident builds on a reputational maelstrom for Monash IVF which was already reeling from an April disclosure that an Australian woman had given birth to a stranger's baby after a fertility doctor accidentally implanted the wrong embryo to a patient in Brisbane in 2023. That mix-up sparked concerns about security protocols at IVF clinics and an industry which is only now in the process of being more regulated. Monash claimed the world's first IVF pregnancy five decades ago and is Australia's second-largest IVF provider, carrying out nearly a quarter of the country's 100,000 assisted reproductive cycles a year, according to industry data. "This mix-up, the second reported incident at Monash IVF, risks shaking confidence not just in one provider but across the entire fertility sector," Hilary Bowman-Smart, a researcher and bioethicist at the University of South Australia. Shares of Monash IVF were down 24% by midsession on Tuesday, against a rising broader market. The stock is just over half its value before the April announcement. "We had thought the Brisbane clinic embryo transfer error was an isolated incident," Craig Wong-Pan, an analyst at RBC Capital Markets, said in a client note. "We believe there is now risk of a greater impact of reputational damage and market share losses to MVF's operations." Monash IVF had already hired a lawyer to run an independent investigation after the Brisbane incident, and said on Tuesday it has extended the scope of that investigation. It added that it was installing interim extra verification safeguards to ensure patient confidence. "Whilst industry-leading electronic witness systems ... are being rolled out across Monash IVF, there remains instances and circumstances whereby manual witnessing is required," the company said. It said it had reported the Melbourne incident to state regulator the Victorian Department of Health and industry licencing body the Reproductive Technology Accreditation Committee (RTAC), part of industry group the Fertility Society of Australia. The health department and RTAC were not immediately available for comment. Reports of transferring a wrong embryo are rare, according to fertility experts, and Monash's Brisbane mix-up was widely reported as the first known case of its kind. ($1 = 1.5330 Australian dollars)

Yahoo
6 hours ago
- Yahoo
Australia's Monash IVF reports second embryo incident in two months
(Reuters) -Australian fertility group Monash IVF on Tuesday reported a new incident related to an embryo transfer, within a couple of months after reporting a similar case where a doctor accidentally implanted the wrong embryo. The latest incident, which occurred on June 5 at the company's Clayton laboratory, has been reported to regulatory bodies and the company's insurer, Monash said, issuing an apology to the impacted couple. The company is also conducting an internal investigation. The firm added that it is implementing additional verification processes and patient confirmation safeguards to prevent similar incidents in the future. The clinic owner in April reported a similar incident where an Australian woman gave birth to a stranger's baby due to a Monash fertility doctor's error. Shares of Monash are down about 31% since the news. The mix-up has drawn attention to an industry that was largely self-regulated until recently and raised concerns about security protocols at IVF clinics. The facilities are regulated by a mix of Australian industry bodies and state government agencies.
Yahoo
7 hours ago
- Yahoo
Berkshire Hathaway Specialty Insurance Launches Life Science, BioTech & Pharmaceutical (LBP) Management Liability Policy in Australia
BOSTON & SYDNEY, June 09, 2025--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance (BHSI) today announced the introduction of a Management Liability Insurance Policy tailored expressly for Life Science, BioTech and Pharmaceutical (LBP) companies in Australia. "The new LBP Management Liability Policy reflects our commitment to Australia's thriving life sciences community and our deep understanding of the challenges start-ups face at every stage of their journey," said Jessica Jefferies, Underwriting Manager, National Brokers, Executive & Professional Lines, BHSI Australia. "Life Sciences is one of the most promising industries in Australia and we are thrilled to be able to provide an innovative solution to support the industry". BHSI's new LBP Management Liability Insurance Policy is specifically for the R&D ecosystem – all stakeholders in Australia's diverse and energetic life sciences sector. The new product offers enhanced cover tailored for life sciences companies, with coverage not found in standard Management Liability policies. BHSI's solution will extend cover and ensure Directors, Officers, Scientific and Medical Advisory Boards all get the benefit of cover as they develop cutting-edge solutions globally. With an understanding of the funding requirements, the product provides two key elements of protection, extending cover for private capital raisings, and not excluding cover in the event of the Company's insolvency. With many Australian life sciences companies looking abroad for clinical development, BHSI's offering has the ability to extend protection to U.S. exposures, recognising the frequent pursuit of FDA approvals by Australian firms. The new solution expands BHSI's existing Management Liability policy wording for private companies and not-for-profits. BHSI is a leading market for Directors and Officers Liability insurance for ASX-listed life sciences companies in Australia. This launch extends that expertise and forms part of BHSI's strategy to provide tailored support for biotech and pharmaceutical customers from start-up to scale. To learn more, contact Berkshire Hathaway Specialty Insurance Company (incorporated in Nebraska, USA) ABN 84 600 643 034, AFS Licence No. 466713 ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident & health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. Berkshire Hathaway Specialty Insurance Company holds financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich. View source version on Contacts MEDIA CONTACTJoAnn Lee / +1 617.936.2937